AKASA
6 known investors
AKASA provides generative AI solutions for healthcare revenue cycle management, helping health systems automate administrative workflows and reduce costs. The company builds AI assistants and workflow automation tools designed for revenue cycle teams at providers, payers, and healthcare organizations.
Also known as AKASA Inc. · Alpha Health
Investors · 6
Company profile
researched Aug 2026AKASA (AKASA Inc., akasa.com) develops generative AI software for the healthcare revenue cycle, aimed at health systems seeking to reduce denials, lower cost-to-collect and relieve administrative burden on revenue cycle staff. The company positions its offering as large language model technology optimized for healthcare and embedded directly in staff workflows, trained on clinical and financial data so that it can interpret clinical context and organization-specific nuances. Company materials describe an approach that combines proprietary GenAI with revenue cycle domain expertise, providing both AI assistants for revenue cycle teams and automation of complex revenue cycle workflows.
The published product set includes a Prebill Optimization Suite that unifies coding and clinical documentation improvement (CDI); Coding Optimizer, which surfaces missed coding opportunities and compliance or quality risks; CDI Optimizer, a GenAI assistant for identifying documentation gaps; AI Advisor, a research assistant that retrieves answers, documents and context for revenue cycle teams; Auth Status, for automated authorization status checks; and Claim Status, for automated claim status retrieval. A 2021 company post describes the platform as built on generative AI and large language models with an "expert-in-the-loop" approach that inserts human judgment and subject matter expertise into the process, and later company text describes building custom large language models for each organization that analyze the full patient record and surface evidence-backed documentation and coding opportunities.
The company was previously known under a different brand and rebranded to AKASA in March 2021, at which time it also adopted the akasa.com domain. The name derives from the Sanskrit word for sky, space or aether — a reference to the medieval "fifth element" — which the company maps to the "four Ps" of healthcare (patients, providers, payers and pharma), positioning itself as the connective layer across them.
Founding story
Company materials state that four founders came together to address high administrative costs in US healthcare that burden patients, providers and payers. The leadership page identifies the co-founders as Malinka Walaliyadde (CEO and board member), Ben Beadle-Ryby (Chief Revenue Officer and board member), Andy Atwal (VP of R&D Special Projects) and Varun Ganapathi, Ph.D. (co-founder and advisor). A founding date is not stated in the sources.
Business model
AKASA sells generative AI software and solutions to healthcare provider organizations for use in revenue cycle operations. The sources do not disclose pricing or contract structures, but customer commentary references improvements in cost-to-collect, gross yield and staff efficiency as the basis of value delivered.
Not specified in the available sources beyond the sale of GenAI-based revenue cycle solutions to health systems.
Traction
Company-reported figures state a client base representing more than 650 hospitals and 6,500 outpatient facilities across all 50 US states, with additional site counters for total client net patient revenue and the volume of clinical documents used for training (numeric values not rendered in the captured page). Customer-attributed outcomes include a 13% decrease in A/R days, 300+ staff hours saved per month, a $30 million gross yield increase and an 86% efficiency improvement, with testimonials from the CFO of Montage Health and the VP/CFO of Methodist Health System.
Latest developments
The most recent company-controlled sources (site copyright 2026) promote a new report stating that 80% of health systems are taking action on generative AI in the revenue cycle, a Prebill Optimization Suite unifying coding and CDI, and content describing work with Cleveland Clinic on generative AI. The current executive team listed includes CEO and co-founder Malinka Walaliyadde, CRO and co-founder Ben Beadle-Ryby, CTO Sanjay Siddhanti, Chief Product Officer Cory Costley, COO Zach Barrett and Chief People Officer Carolyn Satenberg-Stewart. Named investors are Andreessen Horowitz, BOND and Costanoa Ventures.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
The company describes itself as the leading provider of generative AI solutions for the healthcare revenue cycle and cites its own survey data indicating broad health system interest in GenAI for the revenue cycle (80% taking action; 60% eyeing it for the revenue cycle). A press release referenced on the homepage says AKASA was named among fastest growing generative AI startups to watch. Independent third-party market share or ranking data is not present in the sources.
AKASA emphasizes combining revenue cycle operating expertise with generative AI tuned to healthcare rather than general-purpose models, custom large language models built per organization, analysis of the full patient record with evidence-backed recommendations, an expert-in-the-loop process, and a holistic approach that spans automation and ongoing optimization — the latter cited by a customer CFO as a differentiator versus other vendors evaluated.
Technology
Generative AI and large language models adapted for healthcare and the revenue cycle, trained on clinical and financial data and on a stated corpus of clinical documents. The company describes optimizing the class of generative AI that powers ChatGPT for healthcare use and embedding it into staff workflows, building custom large language models per organization, analyzing the full patient record to surface evidence-backed documentation and coding opportunities, and applying an expert-in-the-loop design that incorporates human review. Marketing claims include reviewing large volumes of clinical documents within 90 seconds.
Go-to-market
Direct enterprise sales to health systems, supported by content marketing including commissioned industry surveys and reports on generative AI adoption in the revenue cycle, published case studies with named provider CFOs, blog posts and downloadable guides. The site directs prospects to contact the company by phone or email.
Health systems and hospital provider organizations, specifically revenue cycle, coding, clinical documentation improvement and patient financial services teams. Named customer references include Montage Health, Methodist Health System and Cleveland Clinic.
Geography
United States. Clients span all 50 states; the 2021 funding announcement was datelined South San Francisco, California. The company operates as a remote-friendly hybrid organization with employees in 29 states and hubs including the Bay Area, New York City and Denver.
History
In March 2021 the company announced a $60 million Series B round led by BOND with participation from Andreessen Horowitz, Costanoa Ventures and other existing investors, appointed BOND general partner Noah Knauf to its board, and simultaneously introduced the AKASA brand and akasa.com domain, replacing its prior identity. The announcement, issued from South San Francisco, California, cited pandemic-driven financial pressure and remote work as accelerants of health system demand for revenue cycle automation. The company subsequently repositioned around generative AI and large language models, launching a portfolio of prebill coding, CDI, assistant and status-checking products, and by the most recent site content describes a client base spanning 650+ hospitals and 6,500+ outpatient facilities across all 50 US states.
Risks & controversies
The sources contain no reported controversies, litigation or regulatory actions. Notable profile limitations: no disclosed founding date, headquarters address, employee count, revenue or funding total beyond the 2021 Series B; performance and market statistics are largely self-reported or drawn from company-commissioned surveys, and several homepage metrics appear with unrendered numeric values. Note also the existence of an unrelated name twin, the Indian airline Akasa Air (akasaair.com), whose funding news should not be attributed to this company.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Founder mafia
2 people who came through AKASA went on to found or lead other companies.
Competitors · 8
by search overlap
Companies competing with AKASA for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 5
launches, deals, and filingsA press release listed on the company's homepage states AKASA was named among fastest growing generative AI startups to watch; the awarding body and date are not stated in the source.
Company materials state AKASA partners with leading health systems including Cleveland Clinic; a blog post covers lessons from Cleveland Clinic on generative AI.
The company announced a $60 million Series B round led by BOND, with participation from Andreessen Horowitz, Costanoa Ventures and other existing investors, to scale operations, accelerate product delivery, hire, and expand market presence.
$60M source ↗
Noah Knauf, general partner at BOND, joined the company's board in connection with the Series B round.
The company unveiled a new brand identity, AKASA, along with the akasa.com domain, announced from South San Francisco, California.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- AKASAakasa.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does AKASA do?
- AKASA builds generative AI products that automate coding, documentation and status-checking work in hospital revenue cycles.
- Who are AKASA's investors?
- AKASA's investors include Andreessen Horowitz, Coatue Management, Founders Circle Capital, Balaji Srinivasan, Preface Ventures, Refactor Capital.